Management of methicillin-resistant Staphylococcus aureus bacteremia

被引:87
作者
Cosgrove, Sara E. [1 ]
Fowler, Vance G., Jr. [2 ]
机构
[1] Johns Hopkins Univ, Sch Med, Johns Hopkins Med Inst, Baltimore, MD 21287 USA
[2] Duke Univ, Med Ctr, Durham, NC USA
基金
美国国家卫生研究院;
关键词
D O I
10.1086/533595
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Staphylococcus aureus bacteremia and endocarditis are serious infections that demand prompt clinical attention to ensure good outcomes. Of foremost importance is identifying and managing the source of infection and any associated complications. Evaluation for the presence of cardiac involvement is essential because inadequately managed S. aureus endocarditis is life threatening. Thus, physicians must aggressively negotiate treatment paths, considering whether the S. aureus bacteremia is complicated, whether foreign sources of infection should be removed or replaced, and whether surgical intervention is necessary. Selection of an antibiotic treatment is also an essential factor for optimal management. The increasing prevalence of methicillin-resistant S. aureus (MRSA) infections has created a tremendous demand for effective and safe antimicrobial agents other than the historic anti-MRSA agent vancomycin.
引用
收藏
页码:S386 / S393
页数:8
相关论文
共 72 条
[1]  
*ABR PHARM PROD, 2006, STER VANC HYDR
[2]   Staphylococcus aureus bacteremia and endocarditis:: The Grady Memorial Hospital experience with methicillin-sensitive S aureus and methicillin-resistant S aureus bacteremia [J].
Abraham, J ;
Mansour, C ;
Veledar, E ;
Khan, B ;
Lerakis, S .
AMERICAN HEART JOURNAL, 2004, 147 (03) :536-539
[3]   SINGLE OR COMBINATION THERAPY OF STAPHYLOCOCCAL ENDOCARDITIS IN INTRAVENOUS DRUG-ABUSERS [J].
ABRAMS, B ;
SKLAVER, A ;
HOFFMAN, T ;
GREENMAN, R .
ANNALS OF INTERNAL MEDICINE, 1979, 90 (05) :789-791
[5]  
Baddour LM, 2005, CIRCULATION, V111, pE394, DOI 10.1161/CIRCULATIONAHA.105.165564
[6]   Occurrence of MRSA endocarditis during linezolid treatment [J].
Ben Mansour, EH ;
Jacob, E ;
Monchi, M ;
Ledoux, D ;
Canivet, JL ;
De Mol, P ;
Damas, P .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2003, 22 (06) :372-373
[7]  
*BEN VAN LAB, 2004, CLEOC CLIND INJ PACK
[8]   Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers [J].
Benvenuto, Mark ;
Benziger, David P. ;
Yankelev, Sara ;
Vigliani, Gloria .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2006, 50 (10) :3245-3249
[9]   Long-term outcome of infective endocarditis: The impact of early surgical intervention [J].
Bishara, J ;
Leibovici, L ;
Gartman-Israel, D ;
Sagie, A ;
Kazakov, A ;
Miroshnik, E ;
Ashkenazi, S ;
Pitlik, S .
CLINICAL INFECTIOUS DISEASES, 2001, 33 (10) :1636-1643
[10]  
BOUCHER H, 2006, 46 INT C ANT AG CHEM